The weak but significant (ρ = -0.3028, pFDR = 4.59 × 10–12) association of EZH2 expression with sensitivity to I-BET-762 is surprising, as earlier reports found that EZH2 loss increased tumor sensitivity to bromodomain inhibitors [101, 102]. This evidence concerns the gene EZH2 and neoplasm.